Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $571.96 | 38 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $178.20 | 11 | $0 (2019) |
| GlaxoSmithKline, LLC. | $107.38 | 7 | $0 (2018) |
| Actelion Pharmaceuticals US, Inc. | $97.12 | 7 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $47.90 | 4 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $44.67 | 3 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $28.88 | 2 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $26.56 | 2 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26.22 | 1 | $0 (2017) |
| Mallinckrodt LLC | $15.03 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $13.59 | 1 | Merck Sharp & Dohme Corporation ($13.59) |
| 2019 | $75.05 | 5 | Gilead Sciences, Inc. ($33.76) |
| 2018 | $115.35 | 8 | Gilead Sciences, Inc. ($45.86) |
| 2017 | $367.97 | 24 | Gilead Sciences Inc ($98.58) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/08/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $13.59 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/09/2019 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $13.01 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/31/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.74 | General |
| 04/26/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $12.41 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/29/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.02 | General |
| 02/15/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: Respiratory | ||||||
| 11/30/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $11.71 | General |
| 10/19/2018 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: RESPIRATORY | ||||||
| 09/28/2018 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $11.77 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/21/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.59 | General |
| 08/17/2018 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $10.52 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/13/2018 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 02/09/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.56 | General |
| 01/11/2018 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $14.98 | General |
| Category: Cardiovascular | ||||||
| 11/27/2017 | GlaxoSmithKline, LLC. | BREO (Drug) | Food and Beverage | In-kind items and services | $10.95 | General |
| Category: RESPIRATORY | ||||||
| 10/27/2017 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $26.22 | General |
| 10/06/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $11.38 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/29/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $16.65 | General |
| 09/15/2017 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: RESPIRATORY | ||||||
| 08/18/2017 | Mallinckrodt LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 08/10/2017 | GlaxoSmithKline, LLC. | BREO (Drug) | Food and Beverage | In-kind items and services | $12.86 | General |
| Category: RESPIRATORY | ||||||
| 07/21/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $13.49 | General |
| 07/14/2017 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $13.65 | General |
| Category: Cardiovascular | ||||||
| 07/07/2017 | Actelion Pharmaceuticals US, Inc. | OPSUMIT MACITENTAN (Drug) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: CARDIOVASCULAR DISORDERS | ||||||
| 06/16/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $16.69 | General |
About Dr. Robert Lukeman, M.D
Dr. Robert Lukeman, M.D is a Pulmonary Disease healthcare provider based in Shreveport, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811093008.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Lukeman, M.D has received a total of $571.96 in payments from pharmaceutical and medical device companies, with $13.59 received in 2020. These payments were reported across 38 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($571.96).
Practice Information
- Specialty Pulmonary Disease
- Location Shreveport, LA
- Active Since 09/15/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1811093008
Products in Payments
- OPSUMIT MACITENTAN (Drug) $97.12
- ZERBAXA (Drug) $47.90
- ELIQUIS (Drug) $44.67
- BREO (Drug) $40.73
- NUCALA (Biological) $35.93
- XARELTO (Drug) $26.56
- FASENRA (Drug) $15.87
- ACTHAR (Biological) $15.03
- LOKELMA (Drug) $13.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Shreveport
Dr. Kirit Patel, M.d, M.D
Pulmonary Disease — Payments: $113,159
Ammar Alqaid, Md, MD
Pulmonary Disease — Payments: $16,562
Ashley Ferraro, Do, DO
Pulmonary Disease — Payments: $3,130
Sukhmani Boparai, Md, MD
Pulmonary Disease — Payments: $2,297
Kimberly Jones, M.d, M.D
Pulmonary Disease — Payments: $1,715
Indira Sastry, M.d, M.D
Pulmonary Disease — Payments: $1,235